Core Viewpoint - 九州通 is expanding its medical beauty business by acquiring control of the listed medical beauty company, 奥园美谷, which has entered a restructuring process [1][3]. Group 1: Investment and Restructuring - 九州通 announced its investment of 6.73 billion yuan to acquire 360 million shares of 奥园美谷, later adjusting the investment to 7.06 billion yuan for 436 million shares [1][3]. - 奥园美谷 has been in financial distress since 2020, leading to continuous losses and a "delisting risk warning" in 2023, with its stock renamed to "*ST美谷" [2]. - As of January 3, 2025, 奥园美谷 received interest from 45 potential investors, including 14 with industry-related backgrounds, despite its debt crisis [2]. Group 2: Strategic Advantages - 九州通 has established a strong presence in the medical beauty sector, having invested in key players and formed strategic partnerships since 2016 [5]. - The company’s medical beauty segment has seen a compound annual growth rate of 111.64% from 2022 to 2024, with sales revenue reaching 9.04 billion yuan in the first three quarters of 2025, a year-on-year increase of 45.84% [6]. - 九州通's medical beauty business leverages a comprehensive supply chain, advanced digital capabilities, and a wide network of over 11,538 medical beauty service institutions across 31 provinces [6]. Group 3: Future Prospects - 九州通 aims to enhance its competitive edge in the beauty and health industry through collaboration with 奥园美谷, focusing on supply chain integration and core product development [6]. - The restructuring investment is expected to positively impact 九州通's medical beauty operations, aligning with its long-term strategic development goals [3].